Literature DB >> 32185390

Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection-United States, 2012-2016.

Kristine M Schmit1, Jonathan M Wortham1, Christine S Ho2, Krista M Powell3.   

Abstract

We analyzed data from 2012 to 2016 for patients who were hospitalized or who died after ≥1 dose of isoniazid-rifapentine for treatment of latent Mycobacterium tuberculosis infection. No patients died; 15 were hospitalized. Nine patients experienced hypotension, and 5 had elevated serum aminotransferases, reinforcing the need for vigilant monitoring during treatment. © Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  adverse; isoniazid; latent; rifapentine; tuberculosis

Year:  2020        PMID： 32185390      PMCID： PMC8020883          DOI： 10.1093/cid/ciaa286

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

1.  Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-12-09       Impact factor: 17.586

2.  A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.

Authors:  Christopher Pease; Brian Hutton; Fatemeh Yazdi; Dianna Wolfe; Candyce Hamel; Pauline Barbeau; Becky Skidmore; Gonzalo G Alvarez
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-03-23       Impact factor: 2.890

3.  Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-03-05       Impact factor: 17.586

4.  Three months of rifapentine and isoniazid for latent tuberculosis infection.

Authors:  Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

5.  Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America.

Authors:  Zachary Taylor; Charles M Nolan; Henry M Blumberg
Journal:  MMWR Recomm Rep       Date:  2005-11-04

6.  Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-04-20       Impact factor: 17.586

7.  High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.

Authors:  Amy L Sandul; Nwabunie Nwana; J Mike Holcombe; Mark N Lobato; Suzanne Marks; Risa Webb; Shu-Hua Wang; Brock Stewart; Phil Griffin; Garrett Hunt; Neha Shah; Asween Marco; Naveen Patil; Leonard Mukasa; Ruth N Moro; John Jereb; Sundari Mase; Terence Chorba; Sapna Bamrah-Morris; Christine S Ho
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

8.  Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Authors:  E E Bliven-Sizemore; T R Sterling; N Shang; D Benator; K Schwartzman; R Reves; J Drobeniuc; N Bock; M E Villarino
Journal:  Int J Tuberc Lung Dis       Date:  2015-09       Impact factor: 2.373

9.  Recent Transmission of Tuberculosis - United States, 2011-2014.

Authors:  Courtney M Yuen; J Steve Kammerer; Kala Marks; Thomas R Navin; Anne Marie France
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

10.  Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.

Authors:  Andrey S Borisov; Sapna Bamrah Morris; Gibril J Njie; Carla A Winston; Deron Burton; Stefan Goldberg; Rachel Yelk Woodruff; Leeanna Allen; Philip LoBue; Andrew Vernon
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-06-29       Impact factor: 17.586
View more
  1 in total

1.  Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy.

Authors:  Hung Ling Huang; Jung Yu Lee; Yu Shu Lo; I Hsin Liu; Sing Han Huang; Yu Wei Huang; Meng Rui Lee; Chih Hsin Lee; Meng Hsuan Cheng; Po Liang Lu; Jann Yuan Wang; Jinn Moon Yang; Inn Wen Chong
Journal:  Clin Infect Dis       Date:  2022-09-14       Impact factor: 20.999
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.